Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have shown remarkable therapeutic efficacy in multiple malignancies26, but their effectiveness in pancreatic cancer is limited26. The gene discussed is PDCD1; the disease is pancreatic neoplasm.